Heron Therapeutics (NASDAQ:HRTX - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.05, Zacks reports. The business had revenue of $40.78 million during the quarter, compared to analysts' expectations of $37.37 million. Heron Therapeutics updated its FY 2025 guidance to EPS.
Heron Therapeutics Trading Down 9.3 %
HRTX stock traded down $0.23 during trading on Monday, reaching $2.24. 3,230,465 shares of the stock were exchanged, compared to its average volume of 1,797,269. The firm has a market capitalization of $340.69 million, a price-to-earnings ratio of -12.44 and a beta of 1.60. The business has a 50 day moving average price of $1.69 and a 200-day moving average price of $1.71. Heron Therapeutics has a 1 year low of $1.04 and a 1 year high of $3.93.
Analysts Set New Price Targets
A number of research analysts have weighed in on HRTX shares. Needham & Company LLC reissued a "buy" rating and issued a $4.00 target price on shares of Heron Therapeutics in a research note on Friday. StockNews.com upgraded Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday.
View Our Latest Research Report on Heron Therapeutics
Heron Therapeutics Company Profile
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More

Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.